UCSF and Mount Sinai scientists study an Achilles' heel of AML

NCI Cancer Center News

UCSF and Mount Sinai scientists study an Achilles' heel of AML

The key to treating one of the most common types of human leukemia may lie within mutations in a gene called FLT3, according to new research led by physician-scientists at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center and the Mount Sinai School of Medicine... The new work also suggests why a handful of older drugs developed to treat acute myeloid leukemia by targeting FTL3 have previously failed in clinical trials. The problem with these drugs was not lack of precision but of power - they were aimed at the right target needed to stop the cancer, but most likely did not hit this target hard enough.

To view the full press release from UCSF, please click here

 

                                        ###

Among the research institutions NCI funds across the United States, it currently designates 66 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer's origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers' research results are often at the forefront of studies in the cancer field.

This text may be reproduced freely. Please credit the National Cancer Institute as the source. Any graphics may be owned by the artist or publisher who created them, and permission may be needed for their reuse.